1-4 of 4
Jason Lickliter
Close
Sort by
Journal Articles

Transmembrane Protease, Serine 6 (TMPRSS6) Antisense Oligonucleotide (IONIS-TMPRSS6-L RX ) Reduces Plasma Iron Levels of Healthy Volunteers in a Phase 1 Clinical Study

Michael McCaleb, PhD, Jason Lickliter, MBBS, PhD, Andrew Dibble, PhD, Eugene Schneider, MD, Mariam Aghajan, Shuling Guo, Steve Hughes, MD MBA, Richard S Geary, PhD, Brett P. Monia, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3634.
https://doi.org/10.1182/blood-2018-99-115339
Published: 2018
Journal Articles

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Federico V Grossi, MDPhD, Pauline Bedwell, Pascal Deschatelets, PhD, Lil Edis, PhD, Cedric G Francois, MDPhD, Patrick J Johnson, PhD, Helen J Richardson, Lisa Tan, Carolina A Vega, Jason Lickliter, MBBS,PhD
Journal: Blood
Blood (2016) 128 (22): 1251.
https://doi.org/10.1182/blood.V128.22.1251.1251
Published: 2016
Journal Articles

Phase II Pilot Study of Imatinib Mesylate Combined with Induction Chemotherapy in Blast-Phase CML and Ph+ ALL.

Jason Lickliter, MD, Chris Arthur, MD, James D’Rozario, MD, Chi-hung Hui, MD, Jeffrey Szer, MD, Kerry Taylor, MD, Anne-Marie Watson, MD, Jennifer McCarron, BSc, Kevin Lynch, MD, Ken Bradstock, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 4682.
https://doi.org/10.1182/blood.V104.11.4682.4682
Published: 2004
Journal Articles

A Small-Molecule Bcl-2 Inhibitor Amplifies NKT-Cell Killing of U937 Lymphoma Cells.

Jason Lickliter, Joanne Cox, Mie Nieda, Henry Lin, Andrew Nicol
Journal: Blood
Blood (2004) 104 (11): 1399.
https://doi.org/10.1182/blood.V104.11.1399.1399
Published: 2004